stay updated with our newsletter

Close this search box.

Interview with Bernard Bihari, MD: Low-dose Naltrexone for Normalizing Immune System Function




BernardBihariMDBernard Bihari, MD, (1931-2010) was the discoverer of the clinical effects of low-dose naltrexone (LDN) in humans. In his groundbreaking clinical trial of patients with HIV/AIDS at Downstate Medical Center in 1985-86, Dr Bihari discovered the significant effectiveness of low-dose naltrexone in protecting the battered immune systems of those who were infected. With that knowledge, he entered private practice in an attempt to counter the then untreatable disease. As Dr Bihari explains below, the immune system normalizing effect of the drug application he discovered applies to a wide range of autoimmune disorders.

Physicians, patients and experts from all over the world will gather in Las Vegas in November to discuss and raise awareness about LDN for therapies related to chronic pain, autoimmune diseases and other conditions. The LDN 2014 AIIC Conference 2014 will take place on the 7th and 8th November at the MEET in Las Vegas with a number of high profile medical experts confirmed to speak. The conference also coincides with LDN Awareness Week 2014 which runs from 2nd-8th November 2014. Link here for more on the conference.

This interview was provided by Dr Bihari’s widow, from a videotape discovered after his death. The interview was transcribed and curated by Julia Schopick, author of Honest Medicine ( and champion of effective, cost-efficient treatments that are neglected by current practice. (Altern Ther Health Med. 2013;19(2):56-65.)

Since this interview, TNI BioTech has obtained the rights to the clinical data and the transfer of the Investigational New Drug (IND) and orphan drug designation for LDN from the US Food and Drug Administration for pancreatic cancer and Crohn’s disease. For more go to

Since Dr. Bihari’s passing in 2010, a LDN Research Trust was set up by a group of multiple sclerosis patients to initiate clinical trials of LDN. The organization has assisted more than 14,000 patients to obtain LDN from a general practitioner or neurologist through the National Health Service in the UK or by prescription in other countries including the United States, Canada, Australia, New Zealand and the West Indies. The organization says they have helped patients with MS, Crohn’s, IBS. ME, some cancers and other immune-related diseases. For more go to and

[button link=””]Read Full Article[/button]



Weekly round-up, access to thought leaders, and articles to help you improve health outcomes and the success of your practice.